This case study explores how a small emerging biopharma (EBP) company engaged IQVIA to refine their clinical development plan for an existing drug targeting interdigital neuroma (foot neuroma).
IQVIA's extensive experience brought critical insights to meet the company's objectives. These included determining outcomes important to various stakeholders including payers, physicians and patients, conducting a market assessment, and preparing a Type C meeting request with FDA to align on regulatory requirements.
Learn how IQVIA's capabilities helped implement real-world and commercial insights into your clinical development planning to drive business growth.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
